Provided by Tiger Trade Technology Pte. Ltd.

ALX Oncology Holdings

1.90
+0.06003.26%
Post-market: 1.900.00000.00%16:36 EDT
Volume:1.06M
Turnover:1.99M
Market Cap:262.73M
PE:-1.65
High:1.93
Open:1.85
Low:1.81
Close:1.84
52wk High:2.66
52wk Low:1.01
Shares:138.28M
Float Shares:94.74M
Volume Ratio:1.80
T/O Rate:1.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1500
EPS(LYR):-1.9000
ROE:-80.65%
ROA:-40.40%
PB:1.93
PE(LYR):-1.00

Loading ...

ALX Oncology shareholders ratify KPMG as auditor for 2026 fiscal year

Reuters
·
Jun 12

ALX Oncology to present at Jefferies Global Healthcare Conference fireside chat

Reuters
·
Jun 01

Analysts Conflicted on These Healthcare Names: Senti Biosciences (SNTI), ALX Oncology Holdings (ALXO) and Argenx Se (ARGX)

TIPRANKS
·
May 18

Analysts’ Opinions Are Mixed on These Healthcare Stocks: ALX Oncology Holdings (ALXO) and Heron Therapeutics (HRTX)

TIPRANKS
·
May 12

ALX Oncology Holdings Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 08

ALX Oncologys' Q1 loss narrows on lower expenses

Reuters
·
May 08

ALX Oncology Holdings Q1 Adj. EPS $(0.15) Beats $(0.22) Estimate

Benzinga Earnings
·
May 08

ALX Oncology Q1 Basic EPS USD -0.17

THOMSON REUTERS
·
May 08

ALX Oncology Q1 Net Income USD -17.927 Million

THOMSON REUTERS
·
May 08

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
May 08

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 08

ALX Oncology says evorpacept-zanidatamab trial shows durable responses in HER2+ breast cancer

Reuters
·
May 07

ALX Oncology’s Evorpacept in Combination With Zanidatamab Generates Promising, Durable Response in Patients With Advanced Her2-Positive Breast Cancer and High Cd47 Expression

THOMSON REUTERS
·
May 07

ALX Oncology Holdings Inc expected to post a loss of 22 cents a share - Earnings Preview

Reuters
·
May 06

ALX Oncology updates financial calendar, schedules first-quarter results conference call

Reuters
·
Apr 30

ALX Oncology Announces That Cd47 Biomarker Data From Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at Esmo Breast Cancer 2026

THOMSON REUTERS
·
Apr 30

ALX Oncology announces annual shareholder meeting webcast

Reuters
·
Apr 23

ALX Oncology publishes 2025 annual report

Reuters
·
Apr 23

ALX Oncology announces annual shareholder meeting via webcast

Reuters
·
Apr 21

BRIEF-Alx Oncology Reports Inducement Grant As Permitted By The Nasdaq Listing Rules

Reuters
·
Apr 18